Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Results
IFF logo

IFF Sells Pharma for $2.6B, Boosts Core EBITDA 7% Comparable

IFF10-QFiling Date: 11/4/2025
International Flavors & Fragrances Inc.
Description

What this story covers

IFF's Q3 2025 10-Q shows 8% sales drop to $2.7B from divestitures, but 7% comparable EBITDA growth signals core resilience in Taste and Scent. $2.7B proceeds deleveraged debt to 2.5x, amid segment reorganization and ongoing risks.

Story snapshot

CompanyInternational Flavors & Fragrances Inc.
TickerIFF
VariantStandard detailed
Duration15:42
Filing type10-Q
PeriodQ3 2025
IndustryIndustrials & Manufacturing
Accession0000051253-25-000049

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in